 This Phase 1 clinical study will aim to determine whether therapeutically adequate dosages of guanabenz are safe and well tolerated in patients with multiple sclerosis MS. It will further provide pharmacokinetic data important for determination of optimal dosing schedule for possible future Phase 2 study. 